Introduction
Colorectal cancer (CRC) is the gastrointestinal cancer with the highest incidence, and the stage of the disease at the time of diagnosis is the most critical factor for patient outcomes (1) . Moreover, progression to metastatic disease affects a large number of cases and it represents the subgroup of patients with the worst prognosis. Despite progressive clinical advances have been carried out in the last decade to decrease or prevent metastasis, patient outcomes are still very poor (2) . It is therefore a clinical challenge to develop alternative therapeutic strategies to improve the survival of these patients.
The protein SET is a PP2A inhibitor (3) that participates in the regulation of a wide variety of molecular processes (4) (5) (6) (7) (8) (9) (10) . Of importance, SET plays an oncogenic role modulating signaling pathways with high relevance in human cancer (11) . For instance, it has been reported that SET activates the transcription factor AP-1, deregulates AKT signaling, inhibits the DNase activity of the tumor suppressor NM23-H1 or negatively regulates p53 acetylation then repressing its activity (12) (13) (14) (15) (16) . Moreover, SET is overexpressed in several neoplasms (17) (18) (19) (20) (21) and it has been proposed as a novel molecular target for anticancer therapy (20) (21) (22) (23) . The transcription factor EVI-1 and the miR-199b have been described to regulate SET expression in acute myeloid leukemia and choriocarcinoma (18, 24) .
As indicated above, SET strongly inhibits PP2A, a tumor suppressor that regulates many signaling pathways, and whose loss of function is involved in cell transformation (11, (25) (26) (27) . Different molecular strategies to inhibit PP2A have been described in transformed cells, including the overexpression of endogenous inhibitors such as SET.
In fact, the inactivation of PP2A in human cancer seems to be a very recurrent and relevant event in human cancer and the potential therapeutic benefits of its pharmacological activation has been investigated in the last years with very promising results (28) (29) (30) . Interestingly, it has been reported that the antitumor effects showed by the PP2A activator FTY720 are mediated by SET in lung cancer (31). Moreover, our group has recently described that PP2A inhibition is a common event in CRC and that its restoration using FTY70 or forskolin induces promising antitumor effects (32) (33) .
In this report, we further investigated the potential relevance of SET in CRC. Analysis by western blot confirmed SET overexpression in CRC cell lines. Moreover, we observed that SET promotes cell growth, colonosphere formation and restores the reduced cell viability induced after PP2A overexpression. Furthermore, we identified that SET induces a resistance in CRC cells to oxaliplatin that is impaired after FTY720 treatment. To determine its clinical relevance we quantified SET in a series of 242 patients with metastatic CRC, observing that SET overexpression is a recurrent molecular event that predicts shorter overall survival, disease-free survival and response to oxaliplatin-based chemotherapy.
Research. 
Materials and Methods

Cell cultures and transfection
The human CRC cell lines SW480 (ATCC CCL-228), WiDr (ATCC CCL-218), DLD-1 (ATCC CCL-221), HT-29 (ATCC HTB-38), SW620 (ATCC CCL-227), (ATCC CCL-247) and LS513 (ATCC CRL-2134) were purchased from American Type Culture Collection (ATCC). Of note, the SW480 and SW620 cell lines are derived from the same patient. Authentication was done by the authors in all cases (LGC Standards).
Cell lines were maintained in RPMI-1640 (Invitrogen) with 10% fetal bovine serum and were grown at 37ºC in a 5% CO2 atmosphere. Media were supplemented with penicillin G (100 U/ml), and streptomycin (0.1 mg/ml). Cells were treated with oxaliplatin (LOHP) (1 µM) (Sigma) and FTY720 (10 µM) (Calbiochem) as previously reported Tissue microarrays (TMA) were constructed. Representative areas of each tumor were carefully selected and three tissue cores (1mm diameter) were obtained using a TMA workstation (T1000 Chemicon). Samples were taken anonymously. The ethical committee and institutional review board approved the project.
Western blot analysis
Protein extracts were isolated using TRIzol Reagent (Invitrogen) following manufacturer´s indications, clarified (12,000xg, 15min, 4ºC), denatured and subjected to SDS-PAGE and Western-blot. Antibodies used were rabbit polyclonal anti-SET (Abcam) and mouse monoclonal anti-βactin (Sigma). Proteins were detected with the appropriate secondary antibodies conjugated to alkaline phospatase (Sigma) by chemiluminescence using Tropix CSPD and Tropix Nitro Block II (Applied Biosystems).
Cell viability assay
Cell proliferation was measured in triplicate wells by MTS assay in 96-well plates using 
PP2A phosphatase activity assays
PP2A assays were performed with cell lysates (50μg) using a PP2A immunoprecipitation phosphatase assay kit (Millipore) as previously described (28) .
Analysis of caspase activation
Quantification of caspase 3/7 activities was carried out using the caspase Glo-3/7 assay kit (Promega Corp.). Briefly, 5 × 10 3 cells were plated in a white-walled 96-well plate, and the Z-DEVD reagent, the luminogenic caspase 3/7 substrate containing a tetrapeptide Asp-Glu-Val-Asp, was added with a 1:1 ratio of reagent to sample. After 90 minutes at room temperature, the substrate cleavage by activated caspase-3 and -7, and the intensity of a luminescent signal was measured by a FLUOstar OPTIMA luminometer (BMG Labtech). Differences in caspase-3/7 activity are expressed as foldchange in luminescence.
Cell cycle analysis
Cells were harvested, pelleted and fixed in 70% ethanol on ice for 1 hour. After two washes in PBS, cell were treated with RNaseA for 30 min at 37ºC and stained with propidium iodide (25 µg/mL) (BD Pharmigen) for 10 min at room temperature in dark conditions before the flow analysis.
Colonospheres
For the generation of colonospheres, 10000 cells were plated in 6-well ultra-low attachment plates (Corning). CRC cell were grown in serum-free medium DMEM/F12+GlutMAX TM -I (Gibco) containing 1% N2 (Gibco), 2% B27 (Gibco), 20 ng/ml human FGF (Sigma) and 50 ng/ml EGF (Sigma). After 7 days, plates were colonosphere, colonospheres were collected and dissociated with trypsin to give single cell suspensions. Viable cells were counted in a Neubauer chamber using a trypan blue exclusion test.
Immunohistochemistry
Tissue sections (3μm) were placed on plus charged glass slides. After deparaffinization in xylene and graded alcohols, heat antigen retrieval was performed in pH9 EDTAbased buffer (Dako). Endogenous peroxidase was blocked by 0.03% hydrogen peroxide for 5 min. Slides were incubated with same primary antibody against SET as described for 60 minutes at room temperature, followed of appropriate anti-Ig horseradish 
Statistical analysis
Statistical analyses were performed using SPSS 20 for windows (SPSS Inc, Chicago Illinois). Overall survival (OS) was defined as the time from the date of surgery to the date of death from any cause or last follow-up. Disease-free survival (DFS) was defined as the time from surgery until any primary, regional or distant recurrence, appearance of a secondary tumor or death. Clinical benefit to oxaliplatin-based chemotherapy was defined as any response or prolongued stable disease (>12 weeks). Kaplan-Meier method and survival comparisons were done with the log-rank test if proportional hazard assumption was fulfilled and Breslow otherwise. The Cox proportional hazards model was adjusted taking into consideration significant parameters in univariate analysis. A P-value less than 0.05 was considered statistically significant. Receiver operating curve (ROC) was used to determine the optimal cutoff point based on progression end point for SET expression as previously described (35) . This work was 
SET overexpression leads to PP2A inhibition
Due to SET has been reported as an endogenous PP2A inhibitor, we analyzed whether SET deregulation can alter the effects of the tumor suppressor PP2A in CRC cells.
Thus, we first confirmed by PP2A assays that ectopic expression of SET and PP2A lead to changes in the PP2A activity. As expected, we observed a PP2A inhibition after SET transfection, whereas SW480, HT-29 and LS513 cells transfected with PP2A showed increased PP2A activity levels. Moreover, overexpression of SET counteracted PP2A activation in cells ectopically expressing PP2A, and those cells showed PP2A activity levels similar to the corresponding controls ( Figure 2A ). These observations were confirmed performing experiments with SET silencing (Supplementary Figure S2A) .
SET restores cell viability after PP2A overexpression
In order to analyze whether SET deregulation can alter the action of PP2A on cell growth, we next studied the effect of SET overexpression after PP2A activation. We To further investigate the biological effects of SET deregulation in CRC, we assessed apoptosis in SW480, HT-29 and LS513 cells ectopically expressing SET, PP2A or both SET and PP2A. In concordance with its ability to impair cell proliferation PP2A
showed a caspase-dependent pro-apoptotic effect that was markedly reduced after SET Figure S2C) . Validation of SET overexpression was performed by both real time PCR and western blot (Supplementary Figure S2D) . Thus, these results suggest that SET overexpression promotes cell proliferation and inhibits the antitumor effects of PP2A in CRC cells.
SET induces a decreased oxaliplatin sensitivity that is restored by FTY720 treatment
In order to assess a potential therapeutic role of SET affecting sensitivity of CRC cells to standard induction chemotherapy drugs used in this disease, we treated SW480 cells with oxaliplatin, alone or after transfection with a specific siRNA against SET.
Interestingly, we observed that SET silencing enhanced sensitivity of SW480 cells to oxaliplatin treatment. These results were confirmed in the HT-29 and LS513 cell lines ( Figure 3A ). When we examined 5-FU alone and in combination with oxaliplatin, higher sensitivity was also found after SET silencing (Supplementary Figure S3A) . Moreover, higher apoptosis was observed in SW480, HT-29 and LS513 cells treated with 5-FU combined with oxaliplatin when SET was silenced (Supplementary Figure   S3B) . We also evaluated the sensitivity to oxaliplatin and 5-FU, observing a higher sensitivity to these drugs after SET silencing (Supplementary Figure S3C) . In concordance with these results, SW480, HT-29 and LS513 cells ectopically expressing SET showed an increased resistance to oxaliplatin. Interestingly, this effect was impaired when these cells were treated with oxaliplatin in combination with FTY720, a drug which showed marked antitumor properties ( Figure 3B a reduction in S phase together with an accumulation in G0/G1. As expected, these results were more evident after FTY720 treatment than after SET silencing (Supplementary Figure S4C) probably because FTY720 acts via both SET and CIP2A inactivation (31-32). Moreover, we observed lower sensitivity of CRC cell lines to oxaliplatin and 5-FU after ectopic expression of SET (Supplementary Figure S4D) . Therefore, these observations suggest that SET is involved in modulating sensitivity of CRC cells to oxaliplatin treatment, and that FTY720 impairs the SET-induced resistance to oxaliplatin.
Prevalence of SET overexpression in metastatic colorectal cancer and its association with molecular and clinical parameters
To study the prevalence and clinical significance of SET overexpression, we quantified 
independent factor associated with OS and PFS ( 
Discussion
The SET oncogene has been reported to be upregulated in several types of cancer and it has been proposed as a candidate to develop novel molecular targeted therapies (21-23).
Our previous results showed that PP2A inactivation is a common event in CRC and we identified SET deregulation as a possible contributing mechanism to inhibit PP2A in a set of 21 samples of patients with primary CRC (32) . These results led us to hypothesized that SET could be playing an important oncogenic role in CRC. Although alterations affecting SET has been described in human cancer, its potential significance in CRC remains unexplored. In this report, we show that SET is deregulated in CRC and plays an oncogenic role promoting cell proliferation and colonosphere formation, impairing PP2A antitumor activities and modulating sensitivity of CRC cells to oxaliplatin treatment. Furthermore, our in vitro and clinical data provides evidences that SET overexpression is a recurrent alteration that predicts adverse outcome and induces a decreased sensibility to oxaliplatin in metastatic CRC, which could be restored by the treatment with oxaliplatin in combination with FTY720.
Our previous findings showed that SET is overexpressed in CRC cell lines (32) . In order to study the functional importance of SET deregulation, we silenced SET with two different specific siRNAs in 5 CRC cell lines and observed that in all cases SET silencing induced a decrease in the cell growth and colonosphere formation ability in both number and size of the spheres formed (Figure 1 and Supplementary Figure S1 ).
These results indicate that SET deregulation is an alteration that plays a potential oncogenic role of SET in CRC.
Since SET deregulation has been reported as one of the molecular mechanisms that lead to PP2A inactivation (11, (17) (18) , we next analyzed the effects of SET regulating PP2A unfortunately, their prognosis is still very poor. Therefore, it is necessary to develop alternative therapeutic strategies that improve the survival of these patients. Importantly, we observed that SET overexpression is a recurrent event (24.8%) that predicts adverse outcome and progression-free survival in patients with metastatic CRC (Figure 4 ).
Additionally, we analyzed SET in a series of 145 CRC patients without metastatic disease, observing a lower prevalence of SET overexpression in this cohort than in the metastatic cohort (13.8 vs 24.8%) ( Tables 1 and 2 ).
The high prevalence of this alteration suggests that SET overexpression is a key mechanism to inhibit PP2A in CRC cells, which could discriminate a subgroup of patients who might benefit from future therapies with PP2A activators. Furthermore, in concordance with the fact that SET silencing induced an increased sensitivity to oxaliplatin treatment in CRC cell lines ( Figure 3A ), we observed that those patients without SET overexpression showed better response to oxaliplatin-based chemotherapy and longer OS and PFS (Figure 4 and Supplementary Figure S6B) . Interestingly, the observation that the PP2A activator FTY720, a drug with a promising preclinical antitumor efficacy in several cancer models including CRC (32, 38) SET (31), is able to impair the resistance induced by SET ( Figure 3B ) would suggest that those patients with SET overexpression could improve their outcomes with a future inclusion of an oxaliplatin-based treatment in combination with FTY720 in the clinical protocols. In addition, the fact that the prognostic impact of SET was more evident in the subgroup of patients younger than 70 years (Supplementary Figure S5C) is very interesting since this subgroup includes those cases susceptible of a more aggressive therapy that could benefit from the treatment with PP2A activators (e.g. FTY720).
The KRAS mutated status is a very high prevalent alteration in metastatic CRC that determines resistance to the monoclonal antibody cetuximab. Interestingly, it has recently reported that FTY720 could resensitize CRC cells to cetuximab, indicating a potential therapeutic relevance for FTY720 in metastatic CRC (39) . Of importance, when we stratify our series by the KRAS mutation status, the SET prognostic impact was particularly strong in those patients with KRAS mutated (p<0.001) (Supplementary Figure S6A) . Our results would suggest that the presence of SET overexpression could cooperate inducing a higher resensitization to cetuximab after FTY720 treatment.
In conclusion, we show that SET overexpression is a recurrent molecular event that plays an oncogenic role in CRC contributing to inactivate the tumor suppressor PP2A.
Moreover, SET overexpression predicts worse outcome and response to oxaliplatinbased therapy and its prognostic value is particularly significant in patients younger than 70 years and in those harboring KRAS mutations. Of importance, our results indicate that SET could serve to define a subgroup of metastatic CRC patients with worse outcome that could benefit by the future incorporation of PP2A-activating drugs such as FTY720 in anticancer protocols. 
